- In June 2024, The US Food and Drug Administration (FDA) has approved Kevzara (sarilumab), developed by Sanofi and Regeneron, for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients who weigh at least 63kg
Frequently Asked Questions
The market is segmented based on Segmentation, By Dosage (Injection and Solution), Route of administration (Subcutaneous and Parenteral), Type (Antirheumatic, Interleukin-6 Receptor Antagonist, and Monoclonal Antibody), Application (Rheumatoid Arthritis, Community-acquired Pneumonia, and Others), Demographic (Adult and Geriatric), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2032
.
The Global Sarilumab Market size was valued at USD 345.10 USD Million in 2024.
The Global Sarilumab Market is projected to grow at a CAGR of 7.45% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
